FDA Clears New Mechanical Blood Clot Removal System for Coronary and Peripheral Vasculature

Control Medical Technology, Park City, Utah, announced the FDA cleared, and the company began shipping, the new Aspire RX-LP6 Rapid-Exchange Mechanical Thrombectomy System to remove fresh blood clots and emboli from coronary and peripheral vasculature. 

When removing blood cots, sometimes subtle, low thrombectomy force is needed; other times, continuous, increased, and/or pulsed force is required. Basic syringes-based thrombectomy devices lack this versatility and many clinicians complain when syringes lose aspiration force as their barrels start to fill with fluid.    

In addition, basic syringes typically aspirate only 30ml at a time, requiring the clinician to repeatedly connect, disconnect, and re-connect syringes. This sequence is slow, inefficient, prone to complications, and can increase staff biohazard risk. 

Electromechanical pumps can create pulsed and/or continuous aspiration force, but can be complex, require the hospital to purchase expensive capital equipment, commit to service contracts, and cost significantly more per patient than basic syringe systems. 

“Aspire technology allows users to instantly start, stop, increase, decrease, maintain, and/or pulse thrombectomy force with a simple user interface and no capital equipment,” said Shawn Fojtik, President of Control Medical Technology. “The Aspire system has been used as a primary thrombectomy tool and in situations where syringe-based devices fail. We look forward to adding more catheters to the line.”  

Control Medical Technology’s Aspire Mechanical Thrombectomy System is now one of the largest FDA-cleared platforms in the United States, with over-the-wire and rapid-exchange catheters powered by a mechanical thrombectomy driver/pump. The platform is protected by 10+ issued and pending patents. 

For more information, call 1-954-534-9345 or visit controlmedtech.com.